These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 8645428)

  • 21. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble low-molecular-mass tumor-associated antigens promote the suppression of rat mammary tumors by tamoxifen and prevent its toxic effect.
    Ben-Hur H; Kossoy G; Zusman I
    Int J Oncol; 2002 Feb; 20(2):413-7. PubMed ID: 11788910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
    Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
    Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling reveals underlying molecular mechanisms of the early stages of tamoxifen-induced rat hepatocarcinogenesis.
    Pogribny IP; Bagnyukova TV; Tryndyak VP; Muskhelishvili L; Rodriguez-Juarez R; Kovalchuk O; Han T; Fuscoe JC; Ross SA; Beland FA
    Toxicol Appl Pharmacol; 2007 Nov; 225(1):61-9. PubMed ID: 17706260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
    Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
    Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells.
    Srinivas G; Annab LA; Gopinath G; Banerji A; Srinivas P
    Mol Carcinog; 2004 Jan; 39(1):15-25. PubMed ID: 14694444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line.
    Parisot JP; Hu XF; DeLuise M; Zalcberg JR
    Br J Cancer; 1999 Feb; 79(5-6):693-700. PubMed ID: 10070856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells.
    Lee TH; Chuang LY; Hung WC
    Oncogene; 1999 Jul; 18(29):4269-74. PubMed ID: 10435640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Brandes-Friesen case reports: how should we interpret the news?
    Roy DJ; MacDonald N
    CMAJ; 1995 Sep; 153(5):569-71. PubMed ID: 7641155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen.
    National Toxicology Program
    Rep Carcinog; 2011; 12():393-6. PubMed ID: 21863100
    [No Abstract]   [Full Text] [Related]  

  • 37. Mice are not men!
    Goldstein N
    Hawaii Med J; 1994 Jun; 53(6):158. PubMed ID: 7915707
    [No Abstract]   [Full Text] [Related]  

  • 38. [Adsorption of cationic amphiphilic drugs to antacids and adsorbents. 3. Adsorption of tricyclic antidepressive agents and neuroleptics in relation to their colloid chemical properties].
    Thomas K; Lieb H
    Pharm Acta Helv; 1985; 60(2):39-47. PubMed ID: 2859603
    [No Abstract]   [Full Text] [Related]  

  • 39. Cell Proliferation and Chemical Carcinogenesis. Symposium proceedings. Triangle Park, North Carolina, January 14-16, 1992.
    Environ Health Perspect; 1993 Dec; 101 Suppl 5():1-302. PubMed ID: 7912185
    [No Abstract]   [Full Text] [Related]  

  • 40. Tamoxifen.
    National Toxicology Program
    Rep Carcinog; 2002; 10():223-4. PubMed ID: 15340980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.